Stocks Health care CORT
NASDAQ · Health careCorcept Therapeutics Inc (CORT)
Corcept Therapeutics Inc brought in $963.6M of revenue over the twelve months to September 30, 2026, up 30.0% from a year earlier. Net income was $162.3M, a net margin of 16.8%. Operating cash flow minus capital spending left $141.8M of free cash flow in fiscal 2025. At September 30, 2026 it held $98.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Corcept Therapeutics Inc
- Net worth
- Corcept Therapeutics Inc has a market value (market cap) of $7.8B at the latest share price, and shareholders' equity of $833.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $761.4M (+12.8% year on year), with net income of $99.7M. Over the 12 months to September 30, 2026: revenue $963.6M, net income $162.3M.
- Cash flow
- In fiscal 2025 operations brought in $142M of cash; after $211K of capital spending, free cash flow was $141.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Corcept Therapeutics Inc's next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Corcept Therapeutics Inc does
Corcept Therapeutics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CORT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $761.4M | $99.7M | $0.82 | $141.8M |
| 2024 | $675M | $141.2M | $1.23 | $196.1M |
| 2023 | $482.4M | $106.1M | $0.94 | $126.5M |
| 2022 | $401.9M | $101.4M | $0.87 | $119.9M |
| 2021 | $366M | $112.5M | $0.89 | $167.4M |
| 2020 | $353.9M | $106M | $0.85 | $150.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CORT ranks in Health care
Latest SEC filings
What Corcept Therapeutics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 64% to $340.5M versus the same quarter last year; diluted EPS $1.01 versus $0.16.
- November 3, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- September 23, 2026Executive or director change8-KCorcept Therapeutics announced that Sean Maduck will retire as President of Endocrinology and Justin Gunn will succeed him effective October 1, 2026.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 32% to $256.1M versus the same quarter last year; diluted EPS $0.36 versus $0.29.
- July 29, 2026
- June 17, 2026Other event 8-K
- June 3, 2026Other event 8-K
- May 29, 2026
What is CORT worth? A DCF from its reported cash flow
Insider trades
What the people running Corcept Therapeutics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $42.6M worth of shares in the last 90 days and bought none on the open market. Most of the selling (90%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Maduck SeanSee Remarks | Exercised options | 13,159 | $108.8K |
| November 3, 2026 | Maduck SeanSee Remarks | Soldpre-planned (10b5-1) | 8,617 | $706.8K |
| November 3, 2026 | Maduck SeanSee Remarks | Soldpre-planned (10b5-1) | 4,542 | $375.5K |
| November 2, 2026 | Vieira Roberto WandenkolkPresident, Oncology | Exercised options | 8,333 | $180.2K |
| November 2, 2026 | Vieira Roberto WandenkolkPresident, Oncology | Soldpre-planned (10b5-1) | 6,657 | $537.4K |
| November 2, 2026 | Vieira Roberto WandenkolkPresident, Oncology | Soldpre-planned (10b5-1) | 1,676 | $136.6K |
| November 2, 2026 | Maduck SeanSee Remarks | Exercised options | 11,841 | $97.9K |
| November 2, 2026 | Maduck SeanSee Remarks | Soldpre-planned (10b5-1) | 11,841 | $964.1K |
Who owns CORT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 8.9% | October 27, 2026 |
| Ingalls & Snyder LLC13G, passive | 6.8% | April 21, 2026 |
| Joseph K. Belanoff13G, passive | 6.3% | February 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 422 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 12,432,023 | +280,747 |
| Renaissance Technologies LLC | 5,261,628 | -421,155 |
| Vanguard Portfolio Management LLC | 5,044,638 | +224,070 |
| Vanguard Capital Management LLC | 4,172,482 | +95,286 |
| Parallel Advisors, LLC | 3,962,177 | -15,227 |
| Fmr LLC | 3,337,618 | +147,426 |
| State Street Corp | 3,279,381 | +78,435 |
| Aqr Capital Management LLC | 2,582,561 | +2,176,356 |
| Geode Capital Management, LLC | 2,532,198 | -181,321 |
| First Trust Advisors LP | 1,829,545 | -343,831 |
| Tang Capital Management LLC | 1,500,000 | 0 |
| UBS Group AG | 1,377,658 | +13,990 |
| Dimensional Fund Advisors LP | 1,318,821 | -234,314 |
| Charles Schwab Investment Management Inc | 1,157,580 | +37,621 |
| Morgan Stanley | 1,137,559 | +118,714 |
| D. E. Shaw & Co., Inc. | 883,001 | -298,347 |
| Cerity Partners LLC | 797,119 | +65,430 |
| Mpm Bioimpact LLC | 771,028 | -214,672 |
| Northern Trust Corp | 753,796 | +110,638 |
| Emerald Advisers, LLC | 748,325 | +542,767 |
Insiders
11 insiders reported holding 7,359,712 shares in total, about $534.4M at the last price.
| Holder | Shares |
|---|---|
| Belanoff Joseph KChief Executive Officer, Director | 2,565,4892,565,489 held indirectly |
| Baker G Leonard JrDirector | 2,241,8931,095,262 held indirectly |
| Mahoney David LDirector | 1,133,5391,133,539 held indirectly |
| Wilson James NDirector | 1,054,5431,054,543 held indirectly |
| Hunt HazelChief Scientific Officer | 255,437 |
| Maduck SeanSee Remarks | 43,93834,000 held indirectly |
| Robb Gary CharlesChief Business Officer | 34,62720,571 held indirectly |
| Mokari AtabakChief Financial Officer | 16,304 |
| Lyon Joseph DouglasSee Remarks | 5,683 |
| Guyer WilliamChief Development Officer | 4,313 |
Questions about CORT
What does Corcept Therapeutics Inc do?
Corcept Therapeutics Inc is a company in the Health care sector, listed on NASDAQ as CORT. Its shares trade on NASDAQ under the ticker CORT.
What is Corcept Therapeutics Inc's net worth?
Corcept Therapeutics Inc has a market value (market cap) of $7.8B at the latest share price, and shareholders' equity of $833.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Corcept Therapeutics Inc profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $162.3M on revenue of $963.6M, a net margin of 16.8%.
How much revenue does Corcept Therapeutics Inc make?
Over the twelve months to September 30, 2026 Corcept Therapeutics Inc reported revenue of $963.6M. That is 30.0% more than a year earlier.
When did Corcept Therapeutics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 4, 2026.
When is Corcept Therapeutics Inc's next earnings report?
Corcept Therapeutics Inc's next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CORT with
Follow CORT
Get an email when Corcept Therapeutics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Corcept Therapeutics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.